vaccine

In reaction to Israel’s announcement to sending surplus vaccines to the Czech Republic, Hungary, Honduras, and Guatemala, Oxfam in the Occupied Palestinian Territory Acting Country Director Dina Jibril said: Israel’s deal to exchange surplus vaccines for UN votes and embassies, while the vast majority of almost 5 million Palestinians living in the occupied West Bank and Gaza are left to wait for the potentially life-saving vaccine is shameful and shortsighted. 

The supply of safe and effective vaccines for all is being artificially rationed because of the protection of exclusive rights and monopolies of pharmaceutical corporations, the People’s Vaccine Alliance said today.

In response to Johnson & Johnson's and Novovax release of Phase 3 Trial results of their respective COVID-19 vaccines, Niko Lusiani, Senior Advisor with Oxfam America, said: 

“Today marks yet another hopeful achievement in the fight against the coronavirus. Thanks to tireless scientific efforts, and funding from taxpayers like you and me, these two new vaccines could help turn the corner in the battle against the COVID-19 pandemic. The speed that the virus is mutating is only reinforcing the need for mass-produced vaccines available to everyone, everywhere, as soon as possible." 

Commenting at the close of the EU council meeting where leaders agreed on a new EU 2030 climate target and discussed the EU’s response to the Covid-19 pandemic, Evelien van Roemburg, head of Oxfam’s EU advocacy office said: "The new, more ambitious, EU 2030 target still falls short of what is needed and what is fair. The EU must take urgent practical steps to deliver above and beyond this target."

“Moderna’s discovery could be a real game-changer in the fight against COVID-19. However, on its own, Moderna can only produce enough vaccine for less than seven percent of the global population by the end of 2021, almost all of whom will be in rich countries," said Anna Marriott, Oxfam’s Health Policy Manager, in response to the announcement today from the National Institutes of Health that early data shows Moderna’s COVID-19 vaccine is nearly 95 percent effective.

Responding to the World Bank's proposal of a $12 billion initiative to help poor countries purchase COVID-19 vaccines, Anna Marriott, Health Policy Advisor at Oxfam, said: "The World Bank is right to be concerned about whether poorer countries will be able to afford COVID-19 vaccines and treatments and they should use their influence accordingly."

Survivors of COVID-19 from 37 countries are among almost 1,000 people who have signed an open letter to pharmaceutical industry leaders calling for a ‘people's vaccine’ and treatments that are available to all – free from patents. The letter comes on the eve of a high-level side event about the pandemic at the UN General Assembly in New York.

Wealthy nations representing just 13 percent of the world’s population have already cornered more than half (51 percent) of the promised doses of leading COVID-19 vaccine candidates, Oxfam warned today as the health and finance ministers of G20 countries meet to discuss the global pandemic. 

Despite being largely virtual, this year’s UN General Assembly opening week will remain a vital convening space where leaders and civil society can jointly discuss and tackle some of the gravest issues we face today.

Comment ahead of the Vaccine Alliance pledging conference tomorrow (4 June) that is expected to raise at least US$ 7.4 billion to support the roll out of vaccination programs across the developing world, and establish a new fund to help developing countries buy and distribute a coronavirus vaccine.